Gene therapy and genome editing for primary immunodeficiency diseases

Zhi-Yong Zhang; Adrian J. Thrasher; Fang Zhang

doi:10.1016/j.gendis.2019.07.007

您当前的位置：

首页 >

文章列表页 >

Gene therapy and genome editing for primary immunodeficiency diseases

Review article | 更新时间：2022-06-24

- Gene therapy and genome editing for primary immunodeficiency diseases
- Gene therapy and genome editing for primary immunodeficiency diseases
- Genes & Diseases 2020年7卷第1期
- 作者机构：
  
  1. Department of Immunology and Rheumatology, Children's Hospital of Chongqing Medical University,China
  2. Molecular and Cellular Immunology, Great Ormond Street Institute of Child Health, University Colleage London,UK
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2019.07.007
  中图分类号：
- 纸质出版日期：2020，
  
  网络出版日期：2020-3-1，
扫描看全文
Zhi-Yong Zhang, Adrian J. Thrasher, Fang Zhang. Gene therapy and genome editing for primary immunodeficiency diseases[J]. Genes & Diseases, 2020,7(1).

Zhi-Yong Zhang, Adrian J. Thrasher, Fang Zhang. Gene therapy and genome editing for primary immunodeficiency diseases[J]. Genes & Diseases, 2020,7(1).
Zhi-Yong Zhang, Adrian J. Thrasher, Fang Zhang. Gene therapy and genome editing for primary immunodeficiency diseases[J]. Genes & Diseases, 2020,7(1). DOI： 10.1016/j.gendis.2019.07.007.

Zhi-Yong Zhang, Adrian J. Thrasher, Fang Zhang. Gene therapy and genome editing for primary immunodeficiency diseases[J]. Genes & Diseases, 2020,7(1). DOI： 10.1016/j.gendis.2019.07.007.

摘要

Abstract

In past two decades the gene therapy using genetic modified autologous hematopoietic stem cells (HSCs) transduced with the viral vector has become a promising alternative option for treating primary immunodeficiency diseases (PIDs). Despite of some pitfalls at early stage clinical trials

the field of gene therapy has advanced significantly in the last decade with improvements in viral vector safety

preparatory regime for manufacturing high quality virus

automated CD34 cell purification. Hence

the overall outcome from the clinical trials for the different PIDs has been very encouraging. In addition to the viral vector based gene therapy

the recent fast moving forward developments in genome editing using engineered nucleases in HSCs has provided a new promising platform for the treatment of PIDs. This review provides an overall outcome and progress in gene therapy clinical trials for SCID-X

ADA-SCID

WAS

X- CGD

and the recent developments in genome editing technology applied in HSCs for developing potential therapy

particular in the key studies for PIDs.

关键词

Keywords

Adenosine deaminase deficientChronic granulomatous diseaseGene therapyGenome editingHematopoietic progenitor stem cellsPrimary immunodeficiency diseasesWiskott-Aldrich syndromeX-liked severe combined immunodeficiency

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine

Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges

Prolonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue

An updated review on phenocopies of primary immunodeficiency diseases

Current status and prospects of primary immunodeficiency diseases in Asia